Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1Neoplasms 1Head and Neck Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × terameprocol × Clear all
NCT00057512 2016-02-23

Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

Erimos Pharmaceuticals

Phase 1 Completed
9 enrolled
Head & Neck

Head and Neck Neoplasms

NCT00154089 2016-02-23

A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

Erimos Pharmaceuticals

Phase 1/2 Completed
8 enrolled
Gynecologic

Uterine Cervical Dysplasia

NCT00259818 2008-01-24

Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

Erimos Pharmaceuticals

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡